<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IIR-16008182</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-03-29</date_registration>
      <primary_sponsor>Department of Hematology, Xinqiao Hospital, Third Military Medical University</primary_sponsor>
      <public_title>The multicenter, randomized parallel controlled, open clinical trial of G-CSF priemed low-dose dicitabine in the prophylaxis of high risk acute myeloid leukemia relapse after allogenetic hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>The clinical trial of G-CSF priemed low-dose dicitabine in the prophylaxis of high risk acute myeloid leukemia relapse after allogenetic hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-03-24</date_enrolment>
      <type_enrolment />
      <target_size>G-CSF+Dicitabine:121;control:121;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=13788</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>high risk acute myeloid leukemia</hc_freetext>
      <i_freetext>G-CSF+Dicitabine:G-CSF(150ug d1-6) and dicitabine (5mg/m2 d2-6);control:No intervention;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Lei Gao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13228689635</telephone>
        <email>gaolei7765@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Lei Gao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Shapingba District, Chongqing</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13228689635</telephone>
        <email>gaolei7765@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. High risk AML patients 60-100 days after allo-HSCT and without aGVHD;
2. Aged &lt; 60, KPS score &gt; 60,expected survival &gt; 3 months;
3. No serious organ dysfunction;
4. Informed consent.</inclusion_criteria>
      <agemin>1</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Have serious organ dysfunction;
2. Combined with other cancer need treatment;
3. Presence of clinical signs of brain dysfunction or severe mental illness can not comply with the study protocol;
4. Can not guarantee the completion of the treatment plan and the necessary follow-up observation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>relapse;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>graft versus host disease;overall survival;disease free survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Clinical Founding of Xinqiao Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-03-24</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>